Cantor Fitzgerald Raises Price Target on Pernix Therapeutics (PTX) After Positive Management Meeting

Cantor Fitzgerald maintains a 'Buy' on Pernix Therapeutics (NYSE: PTX) price target raised from $15 to $16.

Analyst, Irina Rivkind, said, "Key takeaways include: (1) The company plans to close 2-5 deals in 2012, one of which is for the branded non-seasonal pediatric product that got delayed from 2011 and several of which are in generics/OTC; (2) We have more clarity about mgmt's horizontal integration strategy and associated mechanics; and (3) Mgmt plans to announce the Theobromine strategy on its next earnings call, which should allow for increased visibility. We continue to like the development of the three verticals in brand, generic, and OTC that are being filled out via the company's aggressive M&A activities, and mgmt's vision for the business (with $1.0 billion in sales as an attainable goal)."

For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.

Shares of Pernix Therapeutics closed at $8.87 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $115 at Wolfe Research
• Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS
• Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens as Pivotal Trial Advances